RxDoctor Payments DataLook up a doctor →

Mark Zenker, MD

Cardiovascular Disease · Nashville, TNNPI 1316985120

Payments from drug & device makers

$992,064in general payments, 2019–2025

Across 286 payments — averaging $3468.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$975K
  • Pfizer$8K
  • Alnylam Pharmaceuticals Inc.$6K
  • Akcea Therapeutics, Inc.$2K
  • Abbott$574
  • Boston Scientific$347
  • plus $980 from 11 others
$824in research payments, 2019–2025

Across 1 payment — averaging $823.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$824

What the payments were for

  • Consulting fees$30,94314%
  • Speaking & faculty fees$157,45170%
  • Travel & lodging$29,84913%
  • Food & beverage$6,6433%
  • Education$470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$992,064 in reported general payments places this provider in the 95th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$166,471
Medicare patients
923
Services billed
3,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis49$1,145,102
CamzyosMavacamten132$1,064,878
EliquisApixaban348$361,169
JardianceEmpagliflozin284$296,344
EntrestoSacubitril/Valsartan105$117,101
XareltoRivaroxaban60$69,866
MultaqDronedarone Hcl24$38,186
Repatha SureclickEvolocumab38$35,148
FarxigaDapagliflozin Propanediol25$22,726
VascepaIcosapent Ethyl40$17,398
Praluent PenAlirocumab17$15,120
Ranolazine ErRanolazine78$13,957
Metoprolol Succinate536$8,372
Icosapent Ethyl17$7,482
Ezetimibe249$6,958

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$7,765$1,506,271397 claims
E.r. Squibb & Sons, L.L.C.Camzyos$974,998$1,064,878132 claims
NovartisEntresto$13$117,101105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →